Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors.
Rastislav Bahleda
No relevant relationships to disclose
Rodrigo Dienstmann
No relevant relationships to disclose
Barbara Adamo
No relevant relationships to disclose
Anas Gazzah
No relevant relationships to disclose
Jeffrey R. Infante
No relevant relationships to disclose
Bob Zhong
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Suso J. Platero
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Hans Smit
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Timothy Perera
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Kim Stuyckens
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Jacqueline Bussolari
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Vijay Peddareddigari
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Jean-Charles Soria
Honoraria - Johnson & Johnson
Feng Roger Luo
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Josep Tabernero
Consultant or Advisory Role - Amgen; Celgene; Chugai Pharma; ImClone Systems; Lilly; Merck KGaA; Millennium; Novartis; Roche; Sanofi ; Taiho Pharmaceutical
Honoraria - Amgen; Merck KGaA; Novartis; Roche; Sanofi